Premium
Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma
Author(s) -
Nakamura Yoshiyuki,
Nakamura Yasuhiro,
Hori Enmi,
Furuta Junichi,
Ishii Yoshiyuki,
Takahashi Takenori,
Kawachi Yasuhiro,
Otsuka Fujio
Publication year - 2009
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2009.04087.x
Subject(s) - medicine , tumor lysis syndrome , complication , hemodialysis , cisplatin , melanoma , chemotherapy , hyperuricemia , allopurinol , surgery , arterial embolization , embolization , uric acid , cancer research
Background Tumor lysis syndrome (TLS) is rare in the treatment of solid tumors, but it may occur in myelolymphoproliferative diseases. Methods A 58‐year‐old man with bulky metastatic melanoma of the liver was treated with transcatheter arterial infusion of cisplatin and embolization therapy. The patient developed classic signs of TLS within 24 h of chemotherapy, including acute renal failure. Results The patient was treated with aggressive hydration, allopurinol, and repeated hemodialysis. He gradually improved and his biochemical markers returned to normal. Conclusion TLS is an uncommon, but potentially life‐threatening, complication in melanoma and other solid tumors. It is important for oncologists to recognize this complication and prevent its development if bulky metastatic disease and several pre‐existing risk factors, such as multiple and bulky liver metastases, elevated lactate dehydrogenase, and hyperuricemia, are present.